183 related articles for article (PubMed ID: 38643188)
1. Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis.
Xia LY; Cao XC; Yu Y
World J Surg Oncol; 2024 Apr; 22(1):106. PubMed ID: 38643188
[TBL] [Abstract][Full Text] [Related]
2. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
Kang S; Lee SH; Lee HJ; Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Lee S; Lee J; Kim SB
Eur J Cancer; 2022 Nov; 176():30-40. PubMed ID: 36183652
[TBL] [Abstract][Full Text] [Related]
3. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
4. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
Qiao W; Guo W; Liu Q; Guo X; Deng M
Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
[TBL] [Abstract][Full Text] [Related]
5. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
[TBL] [Abstract][Full Text] [Related]
7. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
Li JJ; Yu Y; Ge J
Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
[TBL] [Abstract][Full Text] [Related]
8. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases.
Xia LY; Hu QL; Zhang J; Xu WY; Li XS
World J Surg Oncol; 2020 Jun; 18(1):129. PubMed ID: 32539858
[TBL] [Abstract][Full Text] [Related]
10. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
11. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
Ergun Y; Ucar G; Akagunduz B
Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
[TBL] [Abstract][Full Text] [Related]
12. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Pathological Complete Response Rate and Survival Between HER2-Low and HER2-Zero Breast Cancer in Neoadjuvant Chemotherapy Setting: A Systematic Review and Meta-Analysis.
Liu M; Xiang Q; Dai F; Yuan Y; Wu Z; Xiang T
Clin Breast Cancer; 2024 May; ():. PubMed ID: 38821742
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
[TBL] [Abstract][Full Text] [Related]
16. The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer.
Wang W; Zhu T; Chen H; Yao Y
Clin Transl Oncol; 2023 Jun; 25(6):1673-1681. PubMed ID: 36586066
[TBL] [Abstract][Full Text] [Related]
17. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.
Shao Y; Yu Y; Luo Z; Guan H; Zhu F; He Y; Chen Q; Liu C; Nie B; Liu H
Ann Surg Oncol; 2022 Dec; 29(13):8026-8034. PubMed ID: 35933542
[TBL] [Abstract][Full Text] [Related]
18. Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC.
Zheng S; Li L; Chen M; Yang B; Chen J; Liu G; Shao Z; Wu J
Breast; 2022 Jun; 63():177-186. PubMed ID: 35429731
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
Iwase M; Ando M; Aogi K; Aruga T; Inoue K; Shimomura A; Tokunaga E; Masuda N; Yamauchi H; Yamashita T; Iwata H
Breast Cancer Res Treat; 2020 Apr; 180(3):687-694. PubMed ID: 32140811
[TBL] [Abstract][Full Text] [Related]
20. HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study.
Xu W; Jiang Y; Xu L; Li C; Wang J; Liu Z; Xue D; Gu Y; Zhong Z; He S; Wang S; Zhou W; Pan H
Jpn J Clin Oncol; 2023 Jun; 53(6):463-471. PubMed ID: 36757139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]